About two-thirds of people with relapsing forms of multiple sclerosis (MS) remained completely free from relapses over six years of treatment with Zeposia (ozanimod) in the DAYBREAK clinical trial. Most also saw no sustained disability progression during that period and the mean number of new or enlarging lesions…
News
Multiple sclerosis (MS), a neurodegenerative disease thought to affect more than 1.8 million people globally, can impact many aspects of daily life. So for Multiple Sclerosis Awareness Month, observed each March, this year’s focus is on the MS experience and the importance of social connections. Multiple Sclerosis…
Supplements of indole 3-lactate (ILA), a molecule made by gut bacteria, significantly reduced disease severity and promoted myelin repair in mouse models of multiple sclerosis (MS). That’s according to new findings presented by Larissa Jank, PhD, a postdoctoral researcher at Johns Hopkins University, at the Americas Committee for Treatment…
Briumvi (ublituximab-xiiy), an approved treatment for relapsing forms of multiple sclerosis (MS), is now available to patients in Europe, where it’s being marketed by Neuraxpharm. The infusion therapy, developed by TG Therapeutics, was first launched in Germany, with additional rollouts following in other European countries. Under…
Two researchers from The University of Western Australia (UWA) have received grants from MS Australia for work that may help scientists better understand how an immune system gone awry can cause multiple sclerosis (MS). Belinda Kaskow, PhD, a teaching and research fellow at UWA’s School of Biomedical Sciences,…
Both balance and endurance training can help to ease fatigue in people with multiple sclerosis (MS) — but if problems with balance are a concern, then balance training would be the best choice as it targets both fatigue and balance, a small study found. The study, “Fatigue may…
An association between the proteins IgG1 and CXCL10 in the fluid around the brain may help predict the risk of future disease activity for people in the early stages of multiple sclerosis (MS). That’s according to “CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker…
People with multiple sclerosis (MS) have higher amounts of mitochondrial DNA in their spinal fluid, which surrounds the brain and spinal cord, than do their healthy counterparts, a small study found. Mitochondria are small cellular organelles that produce most of the energy needed to power cells. These cell powerhouses…
Black people with multiple sclerosis (MS) scored lower on tests of walking and physical function than did white patients, regardless of social determinants of health such as education or income, a U.S. study reported. These findings add to a growing understanding of how MS manifests in Black people, and…
An imaging feature called the T1-dark rim, which is visible on standard MRI scans of people with multiple sclerosis (MS), could help to identify paramagnetic rim lesions (PRLs), a study suggests. PRLs are regions of chronic active inflammation that cause ongoing nerve damage. They’re associated with disease activity and…
Sweden has a consistently high incidence and prevalence of pediatric-onset multiple sclerosis (PoMS), according to a recently published study. Incidence measures the number of new cases identified during a certain period, while prevalence measures the proportion of people in the population with the condition. Data show the disease is…
About 4 in 5 people with relapsing-remitting multiple sclerosis (RRMS) who receive a stem cell transplant remain free of relapses for at least six years, and this may translate into being able to get back to work, a small study from Norway suggests. The study, “Autologous hematopoietic…
Coupling a noninvasive brain stimulation procedure with an intensive rehabilitation program significantly improved motor function and balance in adults with relapsing-remitting multiple sclerosis (RRMS), a randomized clinical trial finds. High-frequency repetitive transcranial magnetic stimulation (rTMS) is a noninvasive treatment approach that delivers pulses of magnetic fields to modulate nerve…
Complement proteins, especially when activated in the brain and spinal cord, may contribute to nerve cell damage and more severe multiple sclerosis (MS) symptoms, a study that offers insights into a possible therapeutic target suggests. The study, “Complement Activation Is Associated With Disease Severity in Multiple Sclerosis,” was…
Children with multiple sclerosis (MS) who start on high-efficacy therapies experience fewer relapses and reduced MRI disease activity in the following years, compared with those who are treated first with moderate-efficacy therapies, according to a new study. Rates of severe side effects are similar for both groups, but the…
Taking melatonin before bedtime may help balance and muscle strength in people living with multiple sclerosis (MS), according to a study from Tunisia. Those benefits are in addition to making for more restful sleep. While the findings come from a small number of patients, they suggest melatonin supplements may…
More women with multiple sclerosis (MS) got pregnant in recent years, probably linked to a significantly higher use of disease-modifying therapies (DMTs) during pregnancy, according to a nationwide study in France. DMTs are a type of treatment that can alter MS course, by reducing the risk of relapses,…
Treatment options for progressive types of multiple sclerosis (MS) have expanded dramatically over the past decade, and several promising experimental therapies are in late stages of clinical development, a new review paper highlights. The study, “Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and…
The presence in the brain of chronic inflammatory lesions — called paramagnetic rim lesions (PRLs) — in people with multiple sclerosis (MS) is associated with a greater relapse burden and faster disability progression in the long term, according to a new U.S. study. Among more than 150 patients who…
Nabiximols, a cannabis-based oral spray sold as Sativex, was reported to considerably ease spasticity — unusual muscle tightness or stiffness — in about two-thirds of the multiple sclerosis (MS) patients using it for three months in a real-world study in Germany. For most patients, the treatment also…
Bolstered by Phase 2 trial data showing that frexalimab safely reduces the number of brain lesions in people with relapsing forms of multiple sclerosis (MS), developer Sanofi has launched a pair of Phase 3 studies that will test the investigational therapy in relapsing and progressive MS. One of…
Taking caffeine tablets — the equivalent to about two cups of coffee a day — may help people with multiple sclerosis (MS) keep their balance and move more easily, which could aid their quality of life, a small study suggests. While the tablets may…
COMPASS, a digital tool that provides support for managing the daily challenges of living with a long-term health condition such as multiple sclerosis (MS), significantly reduces psychological distress and improves mental health in these patients, data from a randomized clinical trial show. The intervention consists of multiple online modules…
An intermittent fasting (IF) diet may lead to immune and metabolic alterations that ease multiple sclerosis (MS) symptoms and improve quality of life, a recent review of published studies suggests. While evidence from these few small clinical trials indicates an IF diet…
A small clinical trial in Texas is testing whether a noninvasive magnetic brain stimulation procedure can ease the symptoms of overactive bladder in adults with multiple sclerosis (MS). The randomized Phase 2 study (NCT06072703) is ongoing at Houston Methodist Hospital, and is recruiting about 29 women with stable…
Sudo Biosciences has secured an additional $30 million in funding to support the development of two TYK2 inhibitor therapies for multiple sclerosis (MS) and other neurological and skin conditions — and now is aiming to launch clinical trials later this year. With a second close of its Series…
Few multiple sclerosis (MS) clinical trials have used a so-called pragmatic design, which evaluates the effectiveness of interventions in real-life routine practice, a study has found. Because such trials are better able to emulate conditions in real-world clinical practice and provide solid and more actionable evidence to inform treatment…
Under a new agreement, Biogen is transferring ownership of certain digital health solutions — including two existing mobile applications, or apps, offering lifestyle support to people with multiple sclerosis (MS) — to Aptar Digital Health. The collaboration calls for Aptar, part of AptarGroup, to handle product design…
Measuring levels of nitric oxide metabolites in the blood could be a diagnostic biomarker for multiple sclerosis (MS), recent research suggests. The molecules, collectively called NOx, were elevated in the blood of people with relapsing-remitting MS (RRMS) and primary-progressive MS…
An international team of scientists has created a computational model that seeks to give a picture of multiple sclerosis (MS) at multiple biological scales, from tiny molecules to whole cells to organs and its effects on the body overall. “In this study we have…